Omalizumab for severe chronic spontaneous urticaria: Real-life experiences of 280 patients
Zahava Vadasz(Bnai Zion Medical Center), Zev Sthoeger(Odense University Hospital), Keren Mahlab‐Guri(University of Southern Denmark), Gamal Hassoun(Rambam Health Care Campus), Idit Lachover‐Roth(Meir Medical Center), Yuval Tal(Hebrew University of Jerusalem), Migel Stein(Wolfson Medical Center), Shmuel Kivity(Tel Aviv Sourasky Medical Center), Shira Benor(Harvard University), Shira Bezalel‐Rosenberg(Tehran University of Medical Sciences), Menachem Rotem(Emek Medical Center), Ilan Asher(Kaplan Medical Center), Vered Shichter-Confino(Hillel Yaffe Medical Center), Ori Toker(Hadassah Medical Center), Nancy Agmon‐Levin(Sheba Medical Center), Elias Toubi(Bnai Zion Medical Center), Aharon Kessel(Technion – Israel Institute of Technology), Ramit Maoz‐Segal(Sheba Medical Center), Yuri Zeldin(Clalit Health Services), Yael Graif(Rabin Medical Center)
Cited by 54
Related Papers
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k